Handel Soligenix, Inc. - SNGX CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.122 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.024874% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | 0.002651% | ||||||||
Gebyr natten over, tid | 21:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Tidligere luk* | 2.013 |
Åben* | 2.003 |
1-Års Ændring* | 186.96% |
Dagens Spænd* | 1.824 - 2.003 |
52-Ugers Spænd | 1.75-15.00 |
Gennemsnitlig Volumen (10 dage) | 26.42K |
Gennemsnitlig Volumen (3 måneder) | 600.02K |
Market Cap | 5.92M |
P/E-forhold | -100.00K |
Udestående aktier | 2.89M |
Omsætning | 858.49K |
EPS | -5.15 |
Dividend (Udbytte %) | N/A |
Beta | 1.79 |
Næste indtjeningsopgørelse | May 11, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Mar 31, 2023 | 1.914 | -0.089 | -4.44% | 2.003 | 2.003 | 1.824 |
Mar 30, 2023 | 2.013 | -0.260 | -11.44% | 2.273 | 2.273 | 1.963 |
Mar 29, 2023 | 2.143 | 0.000 | 0.00% | 2.143 | 2.143 | 2.143 |
Mar 28, 2023 | 1.944 | 0.080 | 4.29% | 1.864 | 1.993 | 1.864 |
Mar 27, 2023 | 1.854 | -0.050 | -2.63% | 1.904 | 1.904 | 1.794 |
Mar 24, 2023 | 1.764 | -0.010 | -0.56% | 1.774 | 1.774 | 1.764 |
Mar 23, 2023 | 1.744 | -0.200 | -10.29% | 1.944 | 1.944 | 1.744 |
Mar 22, 2023 | 1.774 | -0.229 | -11.43% | 2.003 | 2.013 | 1.774 |
Mar 21, 2023 | 2.043 | -0.160 | -7.26% | 2.203 | 2.203 | 2.013 |
Mar 20, 2023 | 2.133 | -0.070 | -3.18% | 2.203 | 2.273 | 2.093 |
Mar 17, 2023 | 2.312 | -0.180 | -7.22% | 2.492 | 2.492 | 2.123 |
Mar 16, 2023 | 2.492 | -0.189 | -7.05% | 2.681 | 2.751 | 2.492 |
Mar 15, 2023 | 2.701 | -0.020 | -0.74% | 2.721 | 2.831 | 2.701 |
Mar 14, 2023 | 2.761 | -0.110 | -3.83% | 2.871 | 2.891 | 2.731 |
Mar 13, 2023 | 2.831 | -0.129 | -4.36% | 2.960 | 2.970 | 2.831 |
Mar 10, 2023 | 3.030 | 0.090 | 3.06% | 2.940 | 3.030 | 2.940 |
Mar 9, 2023 | 3.090 | 0.299 | 10.71% | 2.791 | 3.150 | 2.791 |
Mar 8, 2023 | 2.741 | 0.020 | 0.74% | 2.721 | 2.821 | 2.721 |
Mar 7, 2023 | 2.801 | -0.060 | -2.10% | 2.861 | 2.861 | 2.801 |
Mar 6, 2023 | 2.950 | -0.020 | -0.67% | 2.970 | 2.970 | 2.950 |
Soligenix, Inc. Events
Tid (UTC) (UTC) | Land | Begivenhed |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total omsætning | 0.82427 | 2.35945 | 4.62992 | 5.24145 | 5.43247 |
Omsætning | 0.82427 | 2.35945 | 4.62992 | 5.24145 | 5.43247 |
Kost af omsætning, Total | 0.72864 | 1.82095 | 3.56742 | 4.59772 | 4.31008 |
Bruttofortjeneste | 0.09563 | 0.5385 | 1.0625 | 0.64373 | 1.12239 |
Totale Driftsudgifter | 13.5436 | 20.9459 | 15.1709 | 14.3004 | 13.0263 |
Salgs/Generelle/Admin. Udgifter, Total | 4.84713 | 3.97923 | 3.48091 | 2.95176 | 3.20916 |
Forskning & Udvikling | 8.38939 | 15.1458 | 8.12261 | 6.75095 | 5.50703 |
Usædvanlig Udgift (Indkomst) | -0.42158 | 0 | |||
Driftsindtægter | -12.7193 | -18.5865 | -10.541 | -9.05898 | -7.5938 |
Renteindkomst (Udgift), Netto Ikke-Drift | -0.90194 | -0.03427 | 0.14116 | 0.15901 | 0.02991 |
Netto Indkomst Før Skat | -13.4157 | -18.5254 | -9.96627 | -8.89998 | -7.56389 |
Netto Indkomst Efter Skat | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Netto Indkomst Før Ekstra Ting | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Netto Indkomst | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Fortyndet Netto Indkomst | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Fortyndet Vægtet Gennemsnit Aktier | 2.67561 | 1.83255 | 1.29183 | 0.87859 | 0.40964 |
Fortyndet EPS Uden Ekstraordinære Ting | -4.69088 | -9.65238 | -7.24211 | -10.1299 | -17.4474 |
Fortyndet Normaliseret EPS | -4.7933 | -9.65238 | -7.24211 | -10.1299 | -17.4474 |
Totale Ekstraordinære Ting | 0 | ||||
Andre, Netto | 0.20552 | 0.09536 | 0.43359 |
Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | |
---|---|---|---|---|---|
Total omsætning | 0.16614 | 0.22864 | 0.18806 | 0.27565 | 0.1862 |
Omsætning | 0.16614 | 0.22864 | 0.18806 | 0.27565 | 0.1862 |
Kost af omsætning, Total | 0.12944 | 0.1933 | 0.09221 | 0.2357 | 0.16627 |
Bruttofortjeneste | 0.0367 | 0.03534 | 0.09585 | 0.03995 | 0.01993 |
Totale Driftsudgifter | 3.24738 | 3.62394 | 4.39069 | 4.7979 | 3.56158 |
Salgs/Generelle/Admin. Udgifter, Total | 1.32625 | 1.38279 | 2.55171 | 2.12639 | 0.91402 |
Forskning & Udvikling | 1.7917 | 2.04784 | 1.74677 | 2.43582 | 2.4813 |
Driftsindtægter | -3.08124 | -3.3953 | -4.20263 | -4.52225 | -3.37538 |
Renteindkomst (Udgift), Netto Ikke-Drift | -0.22776 | -0.12001 | -0.30976 | -0.2345 | -0.28377 |
Andre, Netto | 0 | -0.02639 | 0.16337 | 0.05287 | 0.0716 |
Netto Indkomst Før Skat | -3.309 | -3.5417 | -4.34902 | -4.70388 | -3.58755 |
Netto Indkomst Efter Skat | -3.309 | -2.38676 | -4.34902 | -4.70388 | -3.58755 |
Netto Indkomst Før Ekstra Ting | -3.309 | -2.38676 | -4.34902 | -4.70388 | -3.58755 |
Netto Indkomst | -3.309 | -2.38676 | -4.34902 | -4.70388 | -3.58755 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.309 | -2.38676 | -4.34902 | -4.70388 | -3.58755 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | -3.309 | -2.38676 | -4.34902 | -4.70388 | -3.58755 |
Fortyndet Netto Indkomst | -3.309 | -2.38676 | -4.34902 | -4.70388 | -3.58755 |
Fortyndet Vægtet Gennemsnit Aktier | 2.87239 | 2.86762 | 2.86148 | 2.85986 | 2.71333 |
Fortyndet EPS Uden Ekstraordinære Ting | -1.152 | -0.83231 | -1.51985 | -1.64479 | -1.3222 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | -1.152 | -0.83231 | -1.51985 | -1.64479 | -1.3222 |
Usædvanlig Udgift (Indkomst) | 0 | 0 | 0 | 0 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 26.5695 | 19.467 | 7.49333 | 10.3427 | 9.4158 |
Likvider og Kortsigtede Investeringer | 26.0439 | 18.6767 | 5.42071 | 8.98372 | 7.80949 |
Likvider & Lignende | 26.0439 | 18.6767 | 5.42071 | 8.98372 | 7.80949 |
Totale Tilgodehavender, Netto | 0.24272 | 0.56487 | 1.46288 | 1.20172 | 1.34306 |
Accounts Receivable - Trade, Net | 0.13889 | 0.20377 | 1.01884 | 1.20172 | 0.92625 |
Prepaid Expenses | 0.2829 | 0.22547 | 0.60974 | 0.15728 | 0.26325 |
Total Assets | 26.8699 | 19.8912 | 7.77536 | 10.4917 | 9.54965 |
Property/Plant/Equipment, Total - Net | 0.12838 | 0.25154 | 0.16151 | 0.01963 | 0.03716 |
Intangibles, Net | 0 | 0.0197 | 0.04686 | 0.07395 | |
Total Current Liabilities | 6.29118 | 6.08052 | 6.31208 | 4.21153 | 3.22994 |
Accounts Payable | 2.92554 | 2.12984 | 2.73544 | 2.12622 | 1.75361 |
Accrued Expenses | 3.36563 | 3.6257 | 3.57663 | 2.08532 | 1.47633 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | |||||
Total Liabilities | 16.1473 | 16.1494 | 6.31823 | 4.21153 | 3.22994 |
Total Long Term Debt | 9.85615 | 9.95259 | 0 | 0 | 0 |
Total Equity | 10.7226 | 3.74183 | 1.45714 | 6.28017 | 6.31971 |
Common Stock | 0.04287 | 0.03064 | 0.02175 | 0.01768 | 0.00873 |
Additional Paid-In Capital | 216.403 | 196.95 | 177.006 | 172.436 | 163.581 |
Retained Earnings (Accumulated Deficit) | -205.765 | -193.214 | -175.526 | -166.17 | -157.27 |
Total Liabilities & Shareholders’ Equity | 26.8699 | 19.8912 | 7.77536 | 10.4917 | 9.54965 |
Total Common Shares Outstanding | 42.8735 | 30.6437 | 21.7531 | 17.6828 | 8.73064 |
Other Long Term Assets, Total | 0.17203 | 0.17269 | 0.10083 | 0.0825 | 0.02273 |
Other Equity, Total | 0.04194 | -0.02434 | -0.04501 | -0.00367 | |
Other Liabilities, Total | 0 | 0.1163 | 0.00615 | ||
Current Port. of LT Debt/Capital Leases | 0 | 0.32498 | |||
Long Term Debt | 9.85615 | 9.95259 | |||
Property/Plant/Equipment, Total - Gross | 0.19007 | ||||
Accumulated Depreciation, Total | -0.16785 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 23.4742 | 26.5695 | 29.4445 | 29.3528 | 31.2803 |
Likvider og Kortsigtede Investeringer | 22.8757 | 26.0439 | 28.8675 | 28.98 | 30.5419 |
Likvider & Lignende | 22.8757 | 26.0439 | 28.8675 | 28.98 | 30.5419 |
Totale Tilgodehavender, Netto | 0.24493 | 0.24272 | 0.14796 | 0.22428 | 0.26754 |
Accounts Receivable - Trade, Net | 0.12369 | 0.13889 | 0.04418 | 0.11768 | 0.16172 |
Prepaid Expenses | 0.35364 | 0.2829 | 0.42909 | 0.14859 | 0.47086 |
Total Assets | 23.6746 | 26.8699 | 29.7178 | 29.6103 | 31.5525 |
Property/Plant/Equipment, Total - Net | 0.10292 | 0.12838 | 0.15042 | 0.18485 | 0.21852 |
Property/Plant/Equipment, Total - Gross | 0.19989 | 0.19007 | 0.17828 | 0.17828 | 0.17828 |
Accumulated Depreciation, Total | -0.1722 | -0.16785 | -0.16418 | -0.16104 | -0.15793 |
Other Long Term Assets, Total | 0.09748 | 0.17203 | 0.12284 | 0.0726 | 0.05364 |
Total Current Liabilities | 7.22375 | 6.29118 | 4.79563 | 4.12471 | 4.3007 |
Accounts Payable | 4.51817 | 2.92554 | 1.90578 | 1.48236 | 1.34036 |
Accrued Expenses | 2.70558 | 3.36563 | 2.88985 | 2.64235 | 2.56572 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0 | 0 | 0 | 0.39462 | |
Total Liabilities | 17.0902 | 16.1473 | 14.6633 | 14.0141 | 14.2339 |
Total Long Term Debt | 9.8664 | 9.85615 | 9.84568 | 9.83521 | 9.8476 |
Long Term Debt | 9.8664 | 9.85615 | 9.84568 | 9.83521 | 9.8476 |
Other Liabilities, Total | 0 | 0.02194 | 0.05418 | 0.08563 | |
Total Equity | 6.5845 | 10.7226 | 15.0545 | 15.5962 | 17.3186 |
Common Stock | 0.04295 | 0.04287 | 0.04263 | 0.04008 | 0.04002 |
Additional Paid-In Capital | 216.531 | 216.403 | 216.024 | 213.062 | 212.891 |
Retained Earnings (Accumulated Deficit) | -210.114 | -205.765 | -201.061 | -197.474 | -195.577 |
Other Equity, Total | 0.12459 | 0.04194 | 0.04956 | -0.03206 | -0.03568 |
Total Liabilities & Shareholders’ Equity | 23.6746 | 26.8699 | 29.7178 | 29.6103 | 31.5525 |
Total Common Shares Outstanding | 42.9541 | 42.8735 | 42.6304 | 40.0788 | 40.0205 |
- Årlig
- Pr kvartal
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Netto indkomst/Startlinje | -12.551 | -17.6885 | -9.35559 | -8.89998 | -7.14708 |
Likvider Fra Driftsaktiviteter | -11.7396 | -11.4544 | -7.50957 | -7.24463 | -6.51057 |
Likvider Fra Driftsaktiviteter | 0.03416 | 0.06237 | 0.05445 | 0.04406 | 0.06856 |
Ikke-Likvide Ting | 0.12569 | 5.66242 | 0.65484 | 0.38237 | 0.49571 |
Cash Taxes Paid | 0.00773 | 0.00402 | 0.01113 | 0.00258 | 0.00508 |
Ændringer i Driftskapital | 0.6515 | 0.50931 | 1.13673 | 1.22892 | 0.07224 |
Likvider fra Investeringsaktiviteter | -0.01179 | -0.00715 | -0.02471 | -0.00093 | -0.02635 |
Kapitaludgifter | -0.01179 | -0.00715 | -0.03021 | -0.00193 | -0.02635 |
Likvider fra Financieringsaktiviteter | 19.058 | 24.6766 | 4.00546 | 8.42346 | 5.57384 |
Financiering af Cash-Flow-Ting | -0.66741 | -0.79773 | -0.13208 | -0.25189 | -0.67236 |
Udstedelse (Pensionering) af Aktier, Netto | 19.7316 | 15.0641 | 4.14434 | 8.67535 | 6.2462 |
Udstedelse (Pensionering) af Gæld, Netto | -0.00615 | 10.4103 | -0.0068 | ||
Netto Ændring i Likviditet | 7.36723 | 13.256 | -3.56301 | 1.17423 | -0.96308 |
Andre Investerings-Cash-Flow-Ting, Total | 0.0055 | 0.001 | |||
Udenlandsk Børs Effekter | 0.06064 | 0.04088 | -0.03419 | -0.00367 | |
Likvid Rente Betalt | 0.66872 | 0.03441 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -4.34902 | -12.551 | -7.8471 | -4.25955 | -2.36248 |
Cash From Operating Activities | -3.23884 | -11.7396 | -8.68427 | -5.64415 | -3.98523 |
Cash From Operating Activities | 0.00823 | 0.03416 | 0.02661 | 0.01774 | 0.0089 |
Non-Cash Items | 0.16944 | 0.12569 | -0.02136 | -0.16847 | 0.13296 |
Cash Taxes Paid | 0 | 0.00773 | 0.00738 | 0.00738 | 0.00213 |
Changes in Working Capital | 0.93251 | 0.6515 | -0.84243 | -1.23387 | -1.7646 |
Cash From Investing Activities | -0.00982 | -0.01179 | 0 | 0 | 0 |
Capital Expenditures | -0.00982 | -0.01179 | 0 | 0 | 0 |
Cash From Financing Activities | 0 | 19.058 | 18.8072 | 15.9444 | 15.8557 |
Financing Cash Flow Items | 0 | -0.66741 | -0.62985 | -0.54196 | -0.53796 |
Issuance (Retirement) of Stock, Net | 0 | 19.7316 | 19.4432 | 16.4904 | 16.3957 |
Issuance (Retirement) of Debt, Net | 0 | -0.00615 | -0.00615 | -0.00405 | -0.002 |
Foreign Exchange Effects | 0.08045 | 0.06064 | 0.06791 | 0.00308 | -0.00519 |
Net Change in Cash | -3.16822 | 7.36723 | 10.1908 | 10.3033 | 11.8653 |
Cash Interest Paid | 0.2239 | 0.66872 | 0.44481 | 0.44481 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.7868 | 109402 | 52 | 2022-12-31 | LOW |
First Wilshire Securities Management, Inc. | Investment Advisor/Hedge Fund | 0.8076 | 23333 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7493 | 21647 | -52 | 2022-12-31 | LOW |
Schaber (Christopher J) | Individual Investor | 0.2079 | 6006 | 0 | 2023-01-05 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.1684 | 4864 | 0 | 2022-12-31 | LOW |
Plante Moran Financial Advisors, LLC | Investment Advisor | 0.1654 | 4777 | 0 | 2022-12-31 | LOW |
IHT Wealth Management, LLC | Investment Advisor | 0.1619 | 4677 | 0 | 2022-12-31 | LOW |
Renaissance Technologies LLC | Hedge Fund | 0.1574 | 4547 | 94 | 2022-12-31 | HIGH |
Citadel Advisors LLC | Hedge Fund | 0.1477 | 4268 | 4268 | 2022-12-31 | HIGH |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.1339 | 3869 | 0 | 2022-12-31 | LOW |
Mahrberg Wealth AG | Investment Advisor | 0.1154 | 3333 | 3333 | 2021-12-31 | LOW |
ARGI Investment Services, LLC | Investment Advisor | 0.1081 | 3122 | 0 | 2022-12-31 | LOW |
Fiduciary Trust Company | Bank and Trust | 0.0942 | 2721 | 0 | 2022-12-31 | LOW |
Stewart Capital Advisors, LLC | Investment Advisor | 0.0881 | 2545 | 0 | 2022-12-31 | LOW |
BNY Mellon Asset Management | Investment Advisor | 0.0595 | 1720 | 0 | 2022-12-31 | LOW |
Savant Wealth Management | Investment Advisor | 0.0577 | 1667 | 0 | 2022-12-31 | LOW |
WMS Partners LLC | Investment Advisor | 0.0577 | 1667 | 0 | 2022-12-31 | MED |
Money Concepts Capital Corp | Investment Advisor | 0.0555 | 1603 | 420 | 2022-12-31 | HIGH |
Zeldis (Jerome B) | Individual Investor | 0.0529 | 1528 | 0 | 2023-01-05 | LOW |
Two Sigma Investments, LP | Hedge Fund | 0.0502 | 1451 | 1451 | 2022-12-31 | HIGH |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com Group500K+
Handlende
92K+
Månedlkige, aktive klienter
$53M+
Månedlig investeringsvolumen
$30M+
Hævet hver måned
Handelslommeregner
Udregn dit hypotetiske P&L hvis du havde åbnet en CFD-handel på en given dato (vælg en dato) og lukket den på en anden dato (vælg en dato).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Soligenix, Inc. Company profile
Om Soligenix, Inc.
Soligenix, Inc. er en biofarmaceutisk virksomhed i den sene fase. Virksomheden fokuserer på at udvikle produkter til behandling af sjældne sygdomme. Virksomheden opererer gennem to segmenter: Specialized BioTherapeutics og Public Health Solutions. Specialized BioTherapeutics segmenter omfatter udvikling af HyBryte (SGX301 eller syntetisk hypericin), en fotodynamisk terapi til behandling af kutant T-celle lymfom (CTCL). Segmentet Public Health Solutions omfatter RiVax til beskyttelse mod eksponering for ricin-toksinvaccinkandidat og SGX943 terapeutisk kandidat til behandling af antibiotikaresistente og infektiøse sygdomme. Selskabets udviklingsprogrammer omfatter IDR-teknologi (innate defense regulator), dusquetide (SGX942) til behandling af inflammatoriske sygdomme, oral mucositis i forbindelse med hoved- og halskræft og oral beclomethason 17,21-dipropionat (BDP) til forebyggelse/behandling af gastrointestinale (GI) lidelser, herunder pædiatrisk Crohns sygdom (SGX203).
Industry: | Bio Therapeutic Drugs |
Suite C-10
29 Emmons Drive
08540
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 500.000+ handlende over hele verden, der valgte at handle hos Capital.com